Morgan Stanley analyst Terence Flynn raised the firm’s price target on Regeneron (REGN) to $769 from $768 and keeps an Equal Weight rating on the shares. The firm views the company’s Q4 report as “uneventful.” It sees Phase 3 melanoma data as the next key catalyst for the stock.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Balanced Risk/Reward Keeps Regeneron at Hold Amid Solid Fundamentals and Pipeline Uncertainty
- Regeneron’s Earnings Call: Growth Engines and Rising Costs
- Regeneron Pharmaceuticals: Robust 4Q25 Beat, Underappreciated Pipeline Upside, and 2026 Catalysts Support Buy Rating and $870 Target
- Regeneron price target raised to $870 from $820 at Raymond James
- Options Volatility and Implied Earnings Moves Today, January 30, 2026